이 누리집은 대한민국 공식 전자정부 누리집입니다.
Biz News Korea(Eng)
CJ HealthCare inks technology transfer deal with China’s NCPC GeneTech
- Collected
- 2018.01.31
- Distributed
- 2018.02.01
- Source
- Go Direct
CJ HealthCare CEO Kang Seok-hee and NCPC GeneTech Biotechnology CEO MaDongJie pose for a photo after signing a technology transfer contract on Tuesday.
NCPC GeneTech, founded in 1998, is a biopharmaceutical unit of China’s North China Pharmaceutical Group Corp. It has a broad operating and marketing network across China.
Under the contract, NCPC will have an exclusive right for CJ-40001’s clinical trials, approval, production and sales in China, and CJ HealthCare will receive royalties in return. The unlisted company did not disclose the value of the deal.
CJ-40001 is a biosimilar version of NESP, the second-generation renal anemia treatment developed by Japanese drug maker Kyowa Hakko Kirin Co. It is effective for treating anemia caused by chronic kidney disease and cancer chemotherapy with reduced administration of once per week or once every two weeks.
The global anemia treatment market was estimated at 8 trillion won ($7.5 billion) as of the end of last year, with second-generation drugs taking up 3 trillion won. It is expected that the Chinese second-generation anemia drug market would grow to 300 billion won. An official from the company said that the contract with NCPC along with its previous technology transfer deal with Japan’s YL Biologics in September last year would help it to broaden its global presence. The company will continue to work hard to expand its business to South East Asia and Latin America, he added.
By Kim Hye-soon and Choi Mira
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]